GoldBamboo.com - Knowledge is strong medicine
  

Phase 1/2 Trial of New Drug Candidate for Eczema, Corgentech Treats First Patient - News


  Not Signed In - Sign In / Register




General Topics A-Z

Phase 1/2 Trial of New Drug Candidate for Eczema, Corgentech Treats First Patient

Tue, 24 May 2005 01:00 PM EST

... CorgentechInc (Nasdaq: CGTK) today announced that the company has begun treatingpatients in a multi-center Phase 1/2 clinical trial of its NF-kappaB Decoy(NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronicskin disease also known as eczema that affects about 15 million adults in theUnited States... click link for more info. ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

July 20, 2008


Page Updated: June 12, 2007
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.